Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways

Abstract

Type 1 diabetes (T1D) represents an autoimmune disease caused by the gradual immune-mediated destruction of the insulin-producing beta cells within the pancreatic islets of Langerhans, resulting in the lifelong need for exogenous insulin therapy. According to recent estimates, T1D currently affects about 8.4 million individuals worldwide. Since a definitive biological cure for this disease is not available yet, there is a great need for novel therapeutic strategies aimed at safely and effectively altering the natural history of the disease during its sequential stages. Ideal therapeutic goals in T1D include the prevention of autoimmune beta-cell destruction, the preservation of residual beta-cell mass and endogenous insulin secretion, the replacement and/or regeneration of beta cells, as well as automated insulin delivery through advanced closed-loop artificial pancreas systems. With this regard, an important research area focused on the identification of a definitive biological cure for T1D is represented by the investigation of immunotherapeutic and beta-cell-protective agents used as disease-modifying therapies to forestall or eliminate insulin dependence. In this commentary, we discuss the reasons why the use of combination therapies targeting the multiple immunometabolic dysfunctions associated with T1D (other than beta-cell autoimmunity) is likely to be more effective in preserving beta cell function in individuals at different stages of T1D, as compared to the use of single therapeutic agents.

Keywords

T1D / autoimmunity / insulin secretion / C-peptide / beta-cell function / beta-cell mass / immunotherapy / beta-cell-protective agents / combination therapy

References

[1] Atkinson MA,Michels AW.Type 1 diabetes.Lancet2014;383:69-82 PMCID:PMC4380133

[2] Paschou SA,Chrousos GP.On type 1 diabetes mellitus pathogenesis.Endocr Connect2018;7:R38-46 PMCID:PMC5776665

[3] Greenbaum CJ,Krischer J.Strength in numbers: opportunities for enhancing the development of effective treatments for type 1 diabetes-the trialnet experience.Diabetes2018;67:1216-25 PMCID:PMC6014559

[4] Gregory GA,Linklater SE.International Diabetes Federation Diabetes Atlas Type 1 Diabetes in Adults Special Interest GroupGlobal incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.Lancet Diabetes Endo2022;10:741-60

[5] Neumann M,Su BL.Encapsulation of stem-cell derived β-cells: a promising approach for the treatment for type 1 diabetes mellitus.J Colloid Interface Sci2023;636:90-102

[6] Chen S,Zou C.Current progress in stem cell therapy for type 1 diabetes mellitus.Stem Cell Res Ther2020;11:275 PMCID:PMC7346484

[7] Skyler JS.Hope vs hype: where are we in type 1 diabetes?.Diabetologia2018;61:509-16

[8] Infante M,Rickels MR.Dual-hormone artificial pancreas for management of type 1 diabetes: recent progress and future directions.Artif Organs2021;45:968-86 PMCID:PMC9059950

[9] Moon SJ,Park CY.Current advances of artificial pancreas systems: a comprehensive review of the clinical evidence.Diabetes Metab J2021;45:813-39 PMCID:PMC8640161

[10] Infante M.Editorial - moving forward on the pathway of targeted immunotherapies for type 1 diabetes: the importance of disease heterogeneity.Eur Rev Med Pharmacol Sci2019;23:8702-4

[11] Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.Ann Intern Med1998;128:517-23

[12] Steffes MW,Jackson M.Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.Diabetes Care2003;26:832-6

[13] Jeyam A,McGurnaghan S.SDRNT1BIO InvestigatorsClinical impact of residual C-peptide secretion in type 1 diabetes on glycemia and microvascular complications.Diabetes Care2021;44:390-8

[14] Suh J,Lee M.Insulin requirement and complications associated with serum C-peptide decline in patients with type 1 diabetes mellitus during 15 years after diagnosis.Front Endocrinol2022;13:869204 PMCID:PMC9061978

[15] Liu W,Cai X.Preserved C-peptide secretion is associated with higher time in range (TIR) on intermittently scanned continuous glucose monitoring in Chinese adults with type 1 diabetes.Endocr Connect2022;11 PMCID:PMC9641764

[16] Deligne C,Mallone R.Personalized immunotherapies for type 1 diabetes: who, what, when, and how?.J Pers Med2022;12:542 PMCID:PMC9031881

[17] Oram RA,Besser RE.The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells.Diabetologia2014;57:187-91 PMCID:PMC3855529

[18] Evans-Molina C.Teplizumab approval for type 1 diabetes in the USA.Lancet Diabetes Endo2023;11:76-7

[19] Herold KC,Long SA.Type 1 Diabetes TrialNet Study GroupAn anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes.N Engl J Med2019;381:603-13 PMCID:PMC6776880

[20] Sims EK,Stier K.Type 1 Diabetes TrialNet Study GroupTeplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.Sci Transl Med2021;13 PMCID:PMC8610022

[21] Atkinson MA.The pathogenic "symphony" in type 1 diabetes: a disorder of the immune system, β cells, and exocrine pancreas.Cell Metab2023;35:1500-18 PMCID:PMC10529265

[22] Mallone R,Rui J.The β-cell in type 1 diabetes pathogenesis: a victim of circumstances or an instigator of tragic events?.Diabetes2022;71:1603-10 PMCID:PMC9490354

[23] Leete P,McDonald TJ.TIGI study teamStudies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis.Diabetologia2020;63:1258-67 PMCID:PMC7228905

[24] Sims EK,Nyalwidhe J.Abnormalities in proinsulin processing in islets from individuals with longstanding T1D.Transl Res2019;213:90-9 PMCID:PMC6783367

[25] Arbelaez AM,Cryer PE.Diabetes Research in Children Network (DirecNet) Study GroupBlunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus.Pediatr Diabetes2014;15:127-34 PMCID:PMC3858506

[26] Farhy LS.Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.Diabetes Obes Metab2011;13 Suppl 1:133-43 PMCID:PMC3289058

[27] Mundinger TO,Foulis AK,Hull RL.Human type 1 diabetes is characterized by an early, marked, sustained, and islet-selective loss of sympathetic nerves.Diabetes2016;65:2322-30 PMCID:PMC4955989

[28] Alexandre-Heymann L,Boitard C,Larger E.Structure and function of the exocrine pancreas in patients with type 1 diabetes.Rev Endocr Metab Disord2019;20:129-49

[29] Foster TP,Campbell-Thompson M,Haller MJ.Exocrine pancreas dysfunction in type 1 diabetes.Endocr Pract2020;26:1505-13 PMCID:PMC8697709

[30] Riddle MC.Rediscovery of the second β-cell hormone: co-replacement with pramlintide and insulin in type 1 diabetes.Diabetes Care2020;43:518-21

[31] Greenbaum CJ,Haller MJ.Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes.Diabetes2012;61:1323-30 PMCID:PMC3357268

[32] Battaglia M,Anderson MS.Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes.Diabetes Care2020;43:5-12 PMCID:PMC6925574

[33] Woittiez NJ.Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray.Immunotherapy2015;7:163-74

[34] Infante M,Fabbri A. The heterogeneity of type 1 diabetes: From immunopathology to immune intervention. Translational Autoimmunity. Elsevier; 2022. pp. 83-104.

[35] Gotfredsen CF,Frandsen EK.Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals.Diabetologia1985;28:933-5

[36] Bowman MA,Darrow BL,Suresh A.Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM.Diabetes1996;45:205-8

[37] McVean J,Beck RW.CLVer Study GroupEffect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial.JAMA2023;329:980-9 PMCID:PMC9960023

[38] Boughton CK,Ware J.CLOuD ConsortiumClosed-loop therapy and preservation of C-peptide secretion in type 1 diabetes.N Engl J Med2022;387:882-93

[39] Haller MJ,Gottlieb PA.Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.J Clin Invest2015;125:448-55 PMCID:PMC4382237

[40] Foster TP,Bruggeman B.Low-dose antithymocyte globulin: a pragmatic approach to treating stage 2 type 1 diabetes.Diabetes Care2024;47:285-9 PMCID:PMC10834389

[41] Pinheiro MM,de Arruda MM.Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study.Arch Endocrinol Metab2023;67:e000652 PMCID:PMC10665061

[42] Yan X,Liu B.Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.Signal Transduct Target Ther2023;8:158 PMCID:PMC10115841

[43] Pinheiro MM,Diniz SN,Infante M.Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes.Int Immunopharmacol2021;95:107518

[44] Vella A.Mechanism of action of DPP-4 inhibitors--new insights.J Clin Endocrinol Metab2012;97:2626-8 PMCID:PMC3410278

[45] Dicker D.DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.Diabetes Care2011;34 Suppl 2:S276-8 PMCID:PMC3632192

[46] Drucker DJ.Mechanisms of action and therapeutic application of glucagon-like peptide-1.Cell Metab2018;27:740-56

[47] Rabinovitch A,Lagunas-Rangel FA.Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes.Front Endocrinol2023;14:1171886 PMCID:PMC10246767

[48] Hartig SM.Paracrine signaling in islet function and survival.J Mol Med2020;98:451-67 PMCID:PMC7899133

[49] Tian J,Yong J.Oral treatment with γ-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice.PLoS One2011;6:e25338 PMCID:PMC3178643

[50] Téllez N,Escoriza J,Montanya E.Gastrin treatment stimulates β-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats.Endocrinology2011;152:2580-8

[51] Buteau J.GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.Diabetes Metab2008;34 Suppl 2:S73-7

[52] Hare KJ,Asmar M,Knop FK.The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.Diabetes2010;59:1765-70 PMCID:PMC2889777

[53] Suarez-Pinzon WL,Yan Y,Atkinson M.Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.Diabetes2008;57:3281-8 PMCID:PMC2584134

[54] Suarez-Pinzon WL,Rabinovitch A.Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice.Cell Transplant2008;17:631-40

[55] Ludvigsson J.Autoantigen treatment in type 1 diabetes: unsolved questions on how to select autoantigen and administration route.Int J Mol Sci2020;21:1598 PMCID:PMC7084272

[56] Peakman M.Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.Diabetes2010;59:2087-93 PMCID:PMC2927927

[57] Morales AE.GAD-alum immunotherapy in type 1 diabetes mellitus.Immunotherapy2011;3:323-32

[58] Ludvigsson J,Elluru S.Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset type I diabetes: lessons from the DIABGAD randomized pilot trial.Future Sci OA2020;6:FSO604 PMCID:PMC7421935

[59] Ludvigsson J,Vigård T.Combined etanercept, GAD-alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes.Diabetes Metab Res Rev2021;37:e3440

[60] Hannelius U,Ludvigsson J.Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.Diabetologia2020;63:2177-81 PMCID:PMC7476912

[61] Ludvigsson J,Pelikanova T.Intralymphatic glutamic acid decarboxylase with vitamin d supplementation in recent-onset type 1 diabetes: a double-blind, randomized, placebo-controlled phase IIb trial.Diabetes Care2021;44:1604-12 PMCID:PMC8323180

[62] Barcenilla H,Wahlberg J,Casas R.Intralymphatic GAD-alum injection modulates B cell response and induces follicular helper T cells and PD-1+ CD8+ T cells in patients with recent-onset type 1 diabetes.Front Immunol2021;12:797172 PMCID:PMC8791064

[63] Puente-Marin S,Achenbach P,Ludvigsson J.Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.Front Immunol2023;14:1112570 PMCID:PMC9933867

[64] Dandona P,Ghanim H.Semaglutide in early type 1 diabetes.N Engl J Med2023;389:958-9

[65] Ovalle F,Xu G.Verapamil and beta cell function in adults with recent-onset type 1 diabetes.Nat Med2018;24:1108-12 PMCID:PMC6092963

[66] Forlenza GP,Beck RW.CLVer Study GroupEffect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial.JAMA2023;329:990-9 PMCID:PMC9960020

[67] Xu G,Grayson TB.Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes.Nat Commun2022;13:1159 PMCID:PMC8894430

[68] Padda IS,Parmar M. Golimumab. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576392/ [Last accessed on 13 May 2024]

[69] Quattrin T,Steck AK.T1GER Study InvestigatorsGolimumab and beta-cell function in youth with new-onset type 1 diabetes.N Engl J Med2020;383:2007-17

[70] Rigby MR,Li Y,Hedrick JA.Two-year follow-up from the T1GER study: continued off-therapy metabolic improvements in children and young adults with new-onset T1D treated with golimumab and characterization of responders.Diabetes Care2023;46:561-9 PMCID:PMC10020023

[71] Ahmad A,Balis FJ. Baricitinib. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572064/ [Last accessed on 13 May 2024]

[72] Waibel M,So M.BANDIT Study GroupBaricitinib and β-cell function in patients with new-onset type 1 diabetes.N Engl J Med2023;389:2140-50

[73] Priotto G,Fursa IB.Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.BMJ2008;336:705-8 PMCID:PMC2276259

[74] LoGiudice N,Abuan I,Roberts SC.Alpha-difluoromethylornithine, an irreversible inhibitor of polyamine biosynthesis, as a therapeutic strategy against hyperproliferative and infectious diseases.Med Sci2018;6:12 PMCID:PMC5872169

[75] Sims EK,Hull A.Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes.Cell Rep Med2023;4:101261 PMCID:PMC10694631

[76] Tersey SA,Maier B.Protective effects of polyamine depletion in mouse models of type 1 diabetes: implications for therapy.Amino Acids2014;46:633-42 PMCID:PMC3888834

[77] Krogvold L,Ponzi E.Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial.Nat Med2023;29:2902-8 PMCID:PMC10667091

[78] Dunne JL,Atkinson MA.Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes.Diabetologia2019;62:744-53 PMCID:PMC6450860

[79] Krogvold L,Buanes T.Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes.Diabetes2015;64:1682-7

[80] Ramos EL,Chatenoud L.PROTECT Study InvestigatorsTeplizumab and β-cell function in newly diagnosed type 1 diabetes.N Engl J Med2023;389:2151-61